Power Law company profile

Orbital Therapeutics

Biotech & Life Sciences · San Francisco, United States · Founded 2022 Unicorn

Aims to enhance global health by unleashing the full potential of RNA-based medicines to treat human disease

Valuation

$1–2.5B

Latest valuation · 2026

Unlock exact value

Revenue

$1–10M

Latest reported FY

Unlock exact value

Headcount

<100

Current team size

Unlock exact value

Featured in Unicorn$1B+ valuation tier · Power Law dataset 2026

Investors

14 investors on Orbital Therapeutics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Seed 3 investors entered at this stage

Newpath Management

ARCH Venture Partners

Andreessen Horowitz

Series A 11 investors entered at this stage

Agent Capital

Alexandria Venture Investments

Redmile Group

Heritage Medical Systems

Casdin Capital

Invus

Exor

Moore Strategic Ventures

Rellim Capital Management

iGlobe Partners

Abu Dhabi Growth Fund

Global footprint

Where Orbital Therapeutics has talent and traffic

AI talent share

3.7% of workforce is AI talent
(1 of 27 staff)

Core AI00%

Other AI13.7%

Non-AI workforce2696.3%

Workforce by country

1 countries with
team presence

🇺🇸 United States100%

1 country shown

Web traffic by country

4.1K monthly visits
across markets

🇺🇸 United States100%

Top 1 markets shown

Market sentiment

What the market is saying about Orbital Therapeutics

An AI-synthesized read of the highest-engagement posts about Orbital Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Orbital Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

Book a demo Explore company profiles